Literature DB >> 22834682

Superior analgesic effect of H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA), a multifunctional opioid peptide, compared to morphine in a rat model of neuropathic pain.

Megumi Shimoyama, Peter W Schiller, Naohito Shimoyama, Satoshi Toyama, Hazel H Szeto.   

Abstract

H-Dmt-D-Arg-Phe-Lys-NH(2) ([Dmt(1)]DALDA) is a synthetic tetrapeptide with extraordinary selectivity for the mu-opioid receptor and is an extremely potent analgesic. [Dmt(1) ]DALDA is unusual in the way that the greater part of its analgesic potency appears to be produced by its actions in the spinal cord. Furthermore, [Dmt(1) ]DALDA inhibits norepinephrine re-uptake and is a mitochondria-targeted antioxidant. Such characteristics may make [Dmt(1)]DALDA particularly effective against neuropathic pain. The present study was designed to compare the effects of [Dmt(1)]DALDA and morphine on thermal hyperalgesia in an experimental neuropathic pain model. Neuropathic pain was induced in rats by surgical ligation of the L5 spinal nerve, and thermal pain thresholds were assessed by latencies of paw withdrawal to radiant heat. The increase in paw withdrawal latency was greater after the administration of [Dmt(1) ]DALDA than that of morphine in neuropathic rats at doses that were equianalgesic in naïve animals. We conclude that [Dmt(1)]DALDA is more effective than morphine against thermal hyperalgesia in this experimental model of neuropathic pain.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22834682      PMCID: PMC3465489          DOI: 10.1111/cbdd.12003

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  19 in total

1.  A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia.

Authors:  K Hargreaves; R Dubner; F Brown; C Flores; J Joris
Journal:  Pain       Date:  1988-01       Impact factor: 6.961

2.  Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.

Authors:  Claire L Neilan; Adam J Janvey; Elizabeth Bolan; Irena Berezowska; Thi M-D Nguyen; Peter W Schiller; Gavril W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  2003-03-27       Impact factor: 4.030

3.  Synthesis and in vitro opioid activity profiles of DALDA analogues.

Authors:  P W Schiller; T M Nguyen; I Berezowska; S Dupuis; G Weltrowska; N N Chung; C Lemieux
Journal:  Eur J Med Chem       Date:  2000-10       Impact factor: 6.514

4.  Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists and baclofen.

Authors:  T L Yaksh; S V Reddy
Journal:  Anesthesiology       Date:  1981-06       Impact factor: 7.892

5.  Reactive oxygen species (ROS) play an important role in a rat model of neuropathic pain.

Authors:  Hee Kee Kim; Soon Kwon Park; Jun-Li Zhou; Giulio Taglialatela; Kyungsoon Chung; Richard E Coggeshall; Jin Mo Chung
Journal:  Pain       Date:  2004-09       Impact factor: 6.961

6.  An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat.

Authors:  Sun Ho Kim; Jin Mo Chung
Journal:  Pain       Date:  1992-09       Impact factor: 6.961

7.  Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury.

Authors:  Kesheng Zhao; Guo-Min Zhao; Dunli Wu; Yi Soong; Alex V Birk; Peter W Schiller; Hazel H Szeto
Journal:  J Biol Chem       Date:  2004-06-02       Impact factor: 5.157

8.  Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.

Authors:  Guo-Min Zhao; Xuanxuan Qian; Peter W Schiller; Hazel H Szeto
Journal:  J Pharmacol Exp Ther       Date:  2003-10-08       Impact factor: 4.030

9.  Monoamine and opioid interactions in spinal analgesia and tolerance.

Authors:  C W Loomis; K Jhamandas; B Milne; F Cervenko
Journal:  Pharmacol Biochem Behav       Date:  1987-02       Impact factor: 3.533

10.  Global inhibition of reactive oxygen species (ROS) inhibits paclitaxel-induced painful peripheral neuropathy.

Authors:  Mehmet Fidanboylu; Lisa A Griffiths; Sarah J L Flatters
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

View more
  6 in total

1.  [Dmt(1)]DALDA analogues modified with tyrosine analogues at position 1.

Authors:  Yunxin Cai; Dandan Lu; Zhen Chen; Yi Ding; Nga N Chung; Tingyou Li; Peter W Schiller
Journal:  Bioorg Med Chem Lett       Date:  2016-06-03       Impact factor: 2.823

2.  [Dmt(1)]DALDA analogues with enhanced μ opioid agonist potency and with a mixed μ/κ opioid activity profile.

Authors:  Longxiang Bai; Ziyuan Li; Jiajia Chen; Nga N Chung; Brian C Wilkes; Tingyou Li; Peter W Schiller
Journal:  Bioorg Med Chem       Date:  2014-02-19       Impact factor: 3.641

3.  The bifunctional μ opioid agonist/antioxidant [Dmt(1)]DALDA is a superior analgesic in an animal model of complex regional pain syndrome-type i.

Authors:  Peter W Schiller; Thi M-D Nguyen; Amy Saray; Annie Wing Hoi Poon; André Laferrière; Terence J Coderre
Journal:  ACS Chem Neurosci       Date:  2015-09-14       Impact factor: 4.418

Review 4.  Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

Authors:  Aswini Kumar Giri; Victor J Hruby
Journal:  Expert Opin Investig Drugs       Date:  2013-12-13       Impact factor: 6.206

5.  A Cyclic Tetrapeptide ("Cyclodal") and Its Mirror-Image Isomer Are Both High-Affinity μ Opioid Receptor Antagonists.

Authors:  Grazyna Weltrowska; Thi M-D Nguyen; Nga N Chung; JodiAnne Wood; Xiaoyu Ma; Jason Guo; Brian C Wilkes; Yang Ge; André Laferrière; Terence J Coderre; Peter W Schiller
Journal:  J Med Chem       Date:  2016-10-03       Impact factor: 7.446

6.  Mechanistic Understanding of Peptide Analogues, DALDA, [Dmt1]DALDA, and KGOP01, Binding to the mu Opioid Receptor.

Authors:  Maria Dumitrascuta; Marcel Bermudez; Steven Ballet; Gerhard Wolber; Mariana Spetea
Journal:  Molecules       Date:  2020-04-29       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.